source
- Biogen’s early Phase 2 data supports tau-targeting Alzheimer’s approachBiogen has released early Phase 2 results for its experimental Alzheimer’s therapy diranersen, indicating that reducing tau protein levels may lead to cognitive benefits. The findings add to a lon…
- FDA advisory panel votes 9-3 against Capricor's Duchenne therapy deramiocelDuring an FDA Cellular, Tissue, and Gene Therapies Advisory Committee meeting, reviewers focused on the Phase 3 HOPE-3 trial's secondary cardiac endpoint and described the data as very fragile. The…